Dr. Nadine M. Tung

Dr. Partridge received her MD from Cornell University Medical College in 1995. She completed her residency in internal medicine at the Hospital of the University of Pennsylvania and went on to complete fellowships in medical oncology and hematology at DFCI, MGH and BWH. She also received an MPH from Harvard School of Public Health. She is a medical oncologist who cares for adults with breast cancer, with a particular focus on the unique needs of young patients with breast cancer. She also leads efforts to optimize cancer survivorship care and research at DFCI. She completed fellowships in Medical Oncology and Hematology at DFCI, Massachusetts General Hospital and Brigham and Women’s Hospital. Dr. Partridge is rated as an Elite provider by MediFind in Hormone Replacement Therapy (HRT). Her top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, HER-2 Positive Breast Cancer, Hormone Replacement Therapy (HRT), and Salpingo-Oophorectomy.

Rachel Freedman is an Oncologist in Boston, Massachusetts. Dr. Freedman is rated as a Distinguished provider by MediFind in Hormone Replacement Therapy (HRT). Her top areas of expertise are Breast Cancer, Breast Cancer in Men, Angiosarcoma, Inflammatory Breast Cancer, and Hormone Replacement Therapy (HRT). Dr. Freedman is currently accepting new patients.

Dr. Jennifer Ligibel is a Professor at Harvard Medical School, the Director of the Leonard P. Zakim Center for Integrative Therapies and Healthy Living, and the Director of the Center for Faculty Well-Being at the Dana-Farber Cancer Institute. Dr. Ligibel’s research focuses on the impact of lifestyle interventions upon cancer-related outcomes in women with breast cancer. She has conducted a number of studies looking at the impact of exercise and weight loss interventions upon patients’ quality of life and symptoms after cancer diagnosis and is currently leading an NCI-funded Phase III clinical trial that will test the impact of a weight loss intervention upon the risk of disease recurrence in more than 3000 overweight and obese women with early-stage breast cancer. Dr. Ligibel was the Chair of the American Society of Clinical Oncology Subcommittee on Energy Balance, which has developed patient and physician materials to help facilitate healthy lifestyle changes after cancer diagnosis. Dr. Ligibel is rated as a Distinguished provider by MediFind in Hormone Replacement Therapy (HRT). Her top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and Hormone Replacement Therapy (HRT).